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This phase II trial was performed to evaluate the efficacy and tolerability of a new combination of Uracil/Ftorafur (UFT
s)/leucovorin
(LV) and oxaliplatin in patients (pts) with metastatic colorectal cancer (MCRC) who had not received prior chemotherapy for
metastatic disease. Between February 2002 and October 2002, 64 patients received UFT
s 300mgm
 2day
 1 and LV 90mgday
 1
from day 1 to day 14 combined with oxaliplatin 130mgm
 2 on day 1, every 3 weeks. All patients were evaluable for safety analysis
and 58 of 64 patients were eligible for efficacy. Responses were reviewed by an independent review committee. Of the 58 per-
protocol defined assessable patients, 1 complete response and 20 partial responses were observed yielding a response rate of 34%
(95% CI: 22–47). The median response duration was 8.74 months (range 1.6–14). The median time to progression and the median
survival were 5.88 months (95% CI: 4.34–8.21) and 18.2 months (95% CI: 10–20.7), respectively. Diarrhoea and peripheral
neuropathy were the most frequent and predictable toxicities. These events were reversible, noncumulative and manageable. Grade
3 diarrhoea occurred in only 11% of the patients. No grade 4 gastrointestinal toxicity was reported in the study. The incidence of
grade 3/4 (National Cancer Institute Common Toxicity Criteria 2: NCI-CTC 2) peripheral neuropathy was 15%. Haematological
toxicity was of mild to moderate intensity with 10% of the patients with Grade 3/4 neutropenia without any episode of complication.
The TEGAFOX regimen, a new combination using UFT
s/LV and oxaliplatin every 3 weeks is feasible on an outpatient basis. The
combination is safe and active and may offer a promising alternative to the intravenous route. Nevertheless this efficacy results should
be confirmed by randomized phase III trials.
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Colorectal cancer represents a significant global public health
problem, especially in populations with westernized lifestyles.
Colorectal cancer is the fourth commonest cancer worldwide; it
accounts for 9.4 and 10.1% of all cancer in men and women
(Parkin et al, 1998, 1999), respectively.
Following diagnosis, approximately 50% of patients with colo-
rectal cancer subsequently develop locally recurrent or distant
metastatic disease. Treatment of patients with metastatic colorectal
cancer with fluoropyrimidine therapy is well established; however,
initial results with 5-fluorouracil (5-FU) administered as a single
agent, by rapid intravenous (i.v.) injection, were disappointing.
Consequently, more recent research efforts have concentrated on
optimizing the administration of fluoropyrimidine therapy, and
investigating 5-FU in combination with other antitumour agents.
Ftorafur, a prodrug of 5-FU, is converted to 5-FU by hepatic
metabolism and demonstrates almost complete bioavailability
after oral administration (Anttila et al, 1983). While ftorafur has
shown efficacy in a number of solid tumour types (Ansfield et al,
1983; Taguchi, 1997), coadministration with uracil results in
significantly increased 5-FU concentration within the tumour site
(Nakajima et al, 1980, Maeda et al, 1981; Suemasu et al, 1982;
Tsujimoto et al, 1983). UFT
s is a combination of uracil and
ftorafur for oral administration. It was developed as a convenient
treatment to avoid the need for repeated i.v. injections of 5-FU.
UFT
s is available commercially in Japan and Europe.
Two large randomized phase III trials enrolled patients with
metastatic colorectal cancer to either UFT
s (300mgm
 2day
 1)
plus LV (75 or 90mgday
 1) for 28 days every 35 days, or a Mayo
Clinic regimen every 28 days (Douillard et al, 2002) or 35 days
(Carmichael et al, 2002). In the largest study (Douillard et al, 2002)
(n¼816), the oral UFT
s/LV treatment was broadly comparable
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swith the Mayo Clinic regimen with respect to median survival time
(12.4 months vs 13.6 months, respectively; P¼0.63) and overall
response rate (11.7 vs 14.5%, respectively; P¼0.232). Median
time to progression was more favourable for oral UFT
s/LV (3.8
months; P¼0.01) than for i.v. 5-FU/LV (3.5 months). In the
second study Carmichael et al (2002) (n¼380), efficacy as assessed
by time to progression in the oral UFT
s/LV group was comparable
with i.v. 5-FU/LV treatment. In both phase III studies, gastro-
intestinal toxicity, including diarrhoea, stomatitis, nausea, and
vomiting, were more frequent with the Mayo Clinic regimen as
were hand-foot syndrome and myelotoxicity. Use of antibiotics,
growth factors and antiemetics were less frequent with UFT
s/
leucovorin.
The addition of oxaliplatin to first-line treatment with 5-FU/LV
is reported to have significantly increased progression-free
survival and improved response rate in patients with advanced
colorectal cancer compared with 5-FU/LV alone (de Gramont et al,
2000).
Outcomes such as the above provided the motivation for a
phase I dose ranging study of UFT
s/LV plus oxaliplatin (Douillard
and Seitz, 2001). This study evaluated oral UFT
s (from 200–
350mgm
 2day
 1) plus i.v. oxaliplatin (single infusion of 100mg –
130mgm
 2 on day 1 of the treatment cycle) and oral LV (fixed
dose, 90mgday
 1) in 14-day cycles in 21 patients with metastatic
colorectal cancer. Although this study was not designed to
assess efficacy, a partial response was apparent in five of the 18
evaluable patients (overall response 28%). In this phase I study,
the safety was consistent with the tolerability profiles of UFT
s and
oxaliplatin. Gastrointestinal disturbance was associated with the
study treatment combination. Grade 1 or 2 diarrhoea occurred in
43% of patients, grade 3 or 4 in 19% of patients. Nausea/vomiting
was mainly of grade 1 or 2, with 10% of patients reporting grade 3
episodes. Neurosensory toxicity occurred in 86% of patients, but
was of mild to moderate, only reaching grade 3 in one patient.
The maximum tolerated dose of the combination was estab-
lished as: UFT
s 350mgm
 2day
 1, LV 90mgday
 1, oxaliplatin
130mgm
 2, with grade 3 diarrhoea and grade 3 vomiting as the
main dose limiting toxicities (DLTs).
Thus, the recommended dose and schedule for further phase II
trial was UFT 300mgm
 2day
 1 plus leucovorin 90mg daily, on
days 1–14, and i.v. oxaliplatin 130mgm
 2 on day 1 every 3 weeks.
Given the results of this phase I trial, we initiated a phase II
study using this regimen to determine the efficacy and safety of the
combination as first-line treatment in metastatic colorectal cancer
patients
PATIENTS AND METHODS
Patient selection
Male and female patients, age 18–75 years, with histologically or
cytologically confirmed colorectal adenocarcinoma not suitable
for curative surgery, with at least one uni or bidimensionally
measurable target lesion in a nonirradiated area were included in
this multicentre, phase II, open-label study. Further eligibility
criteria included the following: Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1; adequate bone
marrow reserve (absolute neutrophilsX2000mm
3 and platelets
4125000mm
 3), adequate liver (serum bilirubinp1.5 times the
upper limits of normal (ULN), AST and ALTp2.5 times ULN or
p5 times ULN in case of hepatic metastasis) and renal (serum
creatininep1.5 times ULN) functions.
Patients were excluded if they had received previous chemo-
therapy for metastatic disease, or had brain metastases or a
history of other neoplasms (except nonmelanoma skin carcinoma
or cured carcinoma in situ of the cervix), a serious active infec-
tion or other underlying condition that would impair the patient
from receiving study medication, or peripheral neuropathy
Xgrade 1 NCI-CTC 2. Females of childbearing potential had
to have a negative serum or urine pregnancy test within
72h of starting study medication and had to use adequate
contraceptive measures during the study. Pregnant or lactating
women were excluded. Prior adjuvant or neo-adjuvant therapy was
allowed, if stopped at least 4 weeks before study entry, and
providing patients had recovered from the effects of previous
chemotherapy.
Written informed consent was obtained from each participating
patient before entry into study. The study protocol was reviewed
on 08 January 2002 by the French Ethics Committee (CCPPRB) of
Region des Pays de Loire, Nantes, France. The study was designed
according to the current revision of the Declaration of Helsinki
and conducted in accordance with good clinical practice.
Treatment plan and dose modifications guidelines
Treatment administration UFT
s and LV were taken orally in
three divided doses, on a daily basis (i.e. every 8h) on days 1–14
of the cycle at the dose of 300mgm
 2day
 1 and 90mgday
 1,
respectively. The food was not consumed for 1h before and after
UFT
s administration. Since the available capsule strength of
UFT
s is 100mg (based ftorafur), the total daily dosage was
rounded up or down to the nearest 100mg.
If UFT
s was withheld, LV was also omitted. Oxaliplatin was
given at the dose of 130mgm
 2, as a 2-h i.v. infusion in dextrose
5%, on day 1 of each cycle.
Doses of UFT
sand oxaliplatin were based on body surface area
up to a maximum of 2.0m
2; thus the total dose per administration
did not exceed 600mg for UFT and 260mg for oxaliplatin.
Treatment was administered on an outpatient basis every 3 weeks
and consisted of at least two cycles. Duration of treatment was
based on tumour response: patients with stable disease (SD) or
partial response (PR) could receive treatment until progression,
those with complete response (CR) up to four cycles after CR.
Patients were taken off study at any time if progression or
unacceptable toxicity occurred.
Dose modification Dose reductions for both UFT
s and oxali-
platin were based on toxicity from the previous cycle and graded
according to NCI-CTC 2 classification. Up to two dose reductions
for UFT
s (by 50mgm
 2day
 1) and oxaliplatin (by 15mgm
 2)
were allowed. Re-escalation of dosage after a reduction was not
permitted. Doses of oxaliplatin were reduced by one dose level for
persistent paresthesia (418 days) and paresthesia with pain/
functional impairment, lasting 8–18 days. Therapy with oxalipla-
tin and UFT
s/LV was stopped if functional impairment continued
longer than 18 days. UFT
s/LV was not extended beyond day 14 of
the treatment cycle.
Treatment did not resume until haematological recovery
(ANCX1500mm
 3 and platelets X75000mm
 3) and nonhaema-
tological toxicity resolved to baseline or grade p1 (except
alopecia). When therapy restarted, UFT was reduced by 50mgm
 2
in case of grade 4 haematological toxicity, or febrile neutropenia
and grade 3 nonhaematological toxicity (diarrhoea, stomatitis,
nausea/vomiting, skin toxicity). Oxaliplatin was reduced by one
dose level for grade 3 or 4 haematological toxicity, febrile
neutropenia and paresthesia, lasting more than 18 days or any
other grade 4 nonhaematological toxicity.
Pretreatment and follow-up evaluation Within 2 weeks before
initiation of study treatment, all patients were assessed by physical
examination, complete blood cell, differential white blood cell
count, serum biochemistry analysis (sodium, potassium, total
protein, calcium, alkaline phosphatase, AST/ALT, total bilirubin,
LDH, and creatinine), ECG, chest X-ray, and CT-scan of the
abdomen and other sites of the disease when appropriate.
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sDuring study treatment, complete differential blood counts with
platelets and were determined weekly. Serum chemistries includ-
ing, liver and renal functions were assessed prior to each cycle.
Symptoms, body weight, performance status, physical examination
and all adverse events were recorded before each treatment cycle.
Adverse events were monitored using NCI-CTC 2.
Tumour assessments were performed every 6 weeks (two cycles)
by clinical and CT-scan, employing the same method used to
measure the initial targets. Response was determined according
to RECIST criteria (Therasse et al, 2000). In case of partial or
complete response, a second assessment 4 weeks later was
required for confirmation of response; all tumour measurements
were reviewed and confirmed by an independent panel of
radiologists (IRC).
After discontinuation of study treatment, all patients were
followed up every 3 months until death. Patients who disconti-
nued treatment for reasons other than progression were evalu-
ated every 3 months for tumour response until progression
occurred.
Statistical methods
Study objectives and assessment of response The primary
objective of the study was to characterize the clinical efficacy of
the UFT
s/LV/oxaliplatin combination treatment by defining
objective response rate. This was the proportion of evaluable
patients who showed complete and partial responses to treatment.
All patients, who have received at least two cycles of study
treatment and have at least one tumour assessment were
considered evaluable for response. Secondary objectives were to
assess the safety and tolerability of the combination, response
duration, time to progression (TTP), and survival time.
Sample size and statistical considerations The study tested the
hypothesis that the combination of UFT/LV/oxaliplatin would
produce a tumour response rate of 420% in patients with
metastatic colorectal cancer. Two-sided Clopper–Pearson con-
fidence intervals for the objective response rates were calculated
and adjusted for the two-stage design utilized in the study. The
study utilized an optimal two-stage design (Simon, 1989); the first
19 evaluable patients had to demonstrate response to treatment in
at least five patients before the second stage could proceed to enter
the remaining patients.
Duration of response, survival and time to progression were
calculated using the Kaplan–Meier product limit method.
Descriptive statistics were utilized in safety analyses and adverse
event assessments.
RESULTS
Patients characteristics
Between February 2002 and October 2002, 64 patients were
enrolled onto this trial at ten French institutions. All received at
least one cycle study treatment and were evaluable for safety
analysis. Patient characteristics are depicted in Table 1. There were
28 female (44%) and 36 male (56%) with a median age of 68 years
(range: 38–82). The median time from initial diagnosis to study
entry was 2.6 months (range: 0 days – 155 months). In all, 48 (75%)
of patients had synchronous metastasis.
A total of 26 (41%) patients had two or more than two metastatic
sites. The most frequent sites involved were liver (47%), lung (9%),
liver plus lung (20%), lymph nodes (2%), and the peritoneum
(2%). In all, 17 (27%) patients had received previous adjuvant and/
or neo-adjuvant chemotherapy, of whom 100% had been treated
with an i.v. 5-FU-based regimen.
Exposure to treatment
A total of 355 cycles were administered with a median number
of cycles per patient of six (range 1–14). The median duration
of treatment was 18 weeks (range: 3–42 weeks). Dose reduction
of UFT
s was needed in only 5% of the cycles administered (17/355
cycles), mostly due to gastrointestinal toxicity (3% of the cycles).
Dose reduction of oxaliplatin was required in 6% of the cycles,
mainly because of neurotoxicity (4% of the cycles). The median
value of UFT
s and oxaliplatin dose intensity by cycle were
200.0mgm
 2day
 1736.8 and 43.3mgm
 2week
 175.1, respec-
tively, and the relative dose intensity by cycle were 100% (range
0–241.4) and 100% (range 0–110.5) for UFT
s and oxaliplatin
respectively. Reasons for premature study discontinuation (study-
withdrawal before cycle 3) were disease progression in six patients,
adverse events in three patients, patient request in three patients
and death of unknown origin in one patient.
Independent review committee efficacy results
A total of 58 patients were evaluable for response (Table 2). Five
patients were not assessable for response because of early study-
discontinuation as a result of early progression (one patient),
patient refusal to continue treatment after one cycle (one patient),
occurrence of adverse events (three patients) (grade 3 vomiting,
grade 3 diarrhoea, and grade 4 anorexia). One additional patient
was not evaluable after the IRC evaluation because baseline
tumour assessment more than 6 weeks before study entry. A
complete response to study treatment was seen in one patient (2%)
and a partial response in 19 patients (33%). Thus, the objective
tumour response rate in the evaluable patient population was 34%
(95% CI: 22–47). In the intent to treat (ITT) population (n¼64),
the objective response rate was 31% (95% CI: 20–43). Stabilization
of disease lasting for at least 6 weeks was observed in 29 patients
(50%), whereas progressive disease was apparent in nine patients
(15%).
Analysis of Kaplan–Meier survival curves revealed that the
median time to progression (TTP) was 5.88 months (95%
Table 1 Patient and disease characteristics at baseline (n¼64)
Number of patients 64
Male/female (% of patients) 36 (56%)/28(44%)
Median age (range) 68 years (38–82)
Karnofsky performance status (KPS)
0 40 (63%)
1 24 (37%)
Primary disease
Colon 49 (77%)
Rectal 15 (23%)
Number of metastatic sites
1 38 (59%)
2 21 (33%)
42 5 (8%)
Sites of metastasis
Liver 30 (47%)
Lung 6 (9%)
Liver+lung 13 (20%)
Lymph nodes 1 (2%)
Peritoneum 1 (2%)
Others 13 (20%)
Prior adjuvant chemotherapy (5-FU based regimen)
Yes/no 17(27%)/47(73%)
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sconfidence intervals: 4.34–8.21months) and the median survival
18.2 months (95% confidence intervals: 10.00–20.70 months)
(Figure 1).
Safety results (Table 3)
The NCI-CTC 2 was used for adverse event reporting and overall
treatment tolerance was acceptable (Table 3). Neutropenia was
common, but mild to moderate; 35% of patients experienced grade
1 or 2 with only 10% of patients with grade 3 or 4 neutropenia. No
patient experienced febrile neutropenia at any grade. Anaemia was
graded 3 or 4 in only 6% of patients (grade 1 or 2: 58% of patients).
Grade 3 or 4 thrombocytopenia concerned 14% of the patients.
Of the nonhaematological adverse events, gastrointestinal
toxicity and asthenia were most commonly reported. In all, 40%
of patients experienced grade 1 or 2 diarrhoea (grade 3 or 4: 11%
of patients). Other clinically adverse events included grade 3 or 4
nausea/vomiting (11% of the patients), and grade 3 or 4 asthenia
(13%). The incidence of stomatitis and hand-foot syndrome were
low (14 and 3% of the patients, no grade 3/4). Oxaliplatin-related
sensory neuropathy was most commonly evaluated as grade 1
(47% of the patients) or 2 (27% of the patients) while grade 3 and 4
episodes occurred in 13 and 2% of the patients, respectively.
DISCUSSION
Over the last 20 years, solid progress has been made in
chemotherapy for metastatic colorectal cancer. The initial use of
5-FU alone has been replaced by polychemotherapy regimens,
such as 5-FU/leucovorin/irinotecan or 5-FU/leucovorin/oxali-
platin, which achieve median survivals of 20 months. After the
1990s, new 5-FU oral prodrugs have been developed providing a
better quality of life by suppressing the discomfort of drip-line and
possible events related to i.v. injection, such as infection or
extravasation. The increasing emphasis on developing oral agents
with at least comparable efficacy but enhanced tolerability is an
important factor when considering the future care of cancer
patients. In addition, when given the choice, patients express a
strong preference for oral chemotherapy, provided it is as efficient
as standard options intravenous options (Liu et al, 1997; Borner
et al, 2002a).
The safety data that emerged from this study are consistent with
previously reported phase I study treating this patient population
with UFT
splus LV and with oxaliplatin (Douillard and Seitz,
2001). The toxicity profile of the treatment combination, in the
doses and treatment cycles used in this study, was manageable.
Most haematological and nonhaematological adverse events were
mild or moderate in intensity. Grade 4 NCI-CTC 2 events were
rare. The incidence of grade 3/4 sensory neuropathy toxicity was
consistent with previously reported studies treating this patient
population with 5-FU/LV and oxaliplatin (de Gramont et al, 2000).
Many trials have investigated the use of oxaliplatin plus i.v.
5-FU/LV and this combination has become a standard of care for
MCRC. In order to avoid the risk and constraints of infusional
5-FU, substitution of oral fluoropyrimidines like UFT for i.v.
5-FU needs to be explored. In the phase I combination trial, the
combined used of UFT-folinic acid-and oxaliplatin (TEGAFOX)
was tested and the recommended dose for phase II established
as UFT 300mgm
 2day
 1 with leucovorin 90mgday
 1 for 14 days,
and oxaliplatin 130mgm
 2 at day 1 every 3 weeks. UFT/LV in
first-line metastatic colorectal cancer has shown similar activity
in term of response rate and median survival when compared to
Mayo clinic bolus 5-FU/LV regimen (Carmichael et al, 2002;
Douillard et al, 2002). The overall response rate of 34% obtained
with this combination of UFT/LV/oxaliplatin is lower than
those observed with i.v. 5-FU/LV plus oxaliplatin (45–53%) (de
Gramont et al, 2000; Giacchetti et al, 2000; Goldberg et al, 2004).
In addition, regimens with capecitabine and oxaliplatin gave
objective response rates of 45–49% (Borner et al, 2002b; Cassidy
et al, 2004). However, median survival of 18.2 months reported
in our study is comparable to those observed with i.v. 5-FU-LV
plus oxaliplatin combinations (around 20 months) or with other
regimens testing oxaliplatin with capecitabine (16.8–19.5 months).
Another phase II trial was recently published testing the same
association with UFT, LV, and oxaliplatin in patients with
advanced colorectal cancer (Feliu et al, 2004). In all, 84 patients
Table 2 Response rates (IRC assessment)
Evaluable
population (N)
Intent to treat
population (N)
Overall 58 (91%) 64 (100%)
Not assessable 6 (9%)
Complete response (CR) 1 (2%) 1 (2%)
Partial response (PR) 19 (33%) 19 (30%)
Stable disease (SD) 29 (50%) 29 (45 %)
Progressive disease (PD) 9 (15%) 9 (14 %)
ORR 20 (34%) 20 (31%)
95% CI (22–47) (20–43)
Survival (months)
P
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a
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0.0
0.2
0.4
0.6
0.8
1.0
0369 1 2 1 5 1 8 2 1 2 4 2 7
Patients Events
64 42
Figure 1 Median Survival – Kaplan–Meier curve.
Table 3 Toxicity by patient and by cycle (NCI/CTC grade)
By patient By cycle
All grades
(%)
Grade3–4
(%)
All grades
(%)
Grade3–4
(%)
Leucopenia 41 0 21 0
Neutropenia 45 10 23 2
Anaemia 58 6 30 2
Thrombocytopenia 44 14 18 4
Infection 28 10 5 1
Gastrointestinal
Nausea 66 5 33 1
Vomiting 42 6 25 1
Diarrhoea 51 11 22 2
Stomatitis 14 0 6 0
Hand-foot
syndrome
30 1 0
Sensory
neuropathy
89 15 79 3
Asthenia 74 13 33 2
Alopecia 5 0 16 0
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 2) combined with
UFT (390mgm
 2day
 1) and LV from day 1–14. Results were
similar with an objective response rate of 35%, a median time to
progression of 7.3 months and a median survival of 16.8 months. A
high gastrointestinal toxicity conducted the investigators to reduce
the dose of UFT at 300mgm
 2 after the inclusion of the first 16
patients. In addition, the combination of UFT-LV and Oxaliplatin
was evaluated in two other trials including either patients of 70
years or older (Rosati et al, 2005) and patients previously treated
with a fluoropyrimidine-based regimen (Kim et al, 2002). In
elderly patients, the objective response rate was 47% with a median
time to disease progression of 8 months (Rosati et al, 2005). After
failure to fluoropyrimidine-based regimen, the response rate was
12.9% in 31 assessable patients (Kim et al, 2002).
The study outcome suggests that the defined combination
regimen (UFT/LV/oxaliplatin) is a feasible, safe and convenient
outpatient treatment option for patients with nonresectable
metastatic colorectal cancer. Efficacy data should be confirmed
by randomized phase III. In our study and in the trials conducted
by Fe ´liu et al and Rosati et al (2005) the schedule of oxaliplatin
administration was different: 130mgm
 2 every 21 days in our
study and 85mgm
 2 at days 1 and 14 (Feliu et al, 2004) or
65mgm
 2 at days 1 and 8. Efficacy of these three schedules is
probably similar but our schedule should be preferred for the
comfort of patients, reducing the frequency of i.v. administration.
Better understanding of tumour cell biology has actively contri-
buted to the development of novel biological agents that block
certain cell growth events. These new strategies, particularly
inhibition of angiogenesis and Epidermal Growth Factor receptors,
can be used in association with chemotherapy to increase survival.
In the future, we can expect that oral 5-FU prodrugs will replace
i.v. 5-FU in combination with oxaliplatin or irinotecan. The role of
additional agents, such as anti-EGFR compounds or angiogenesis
inhibitors should be defined in the therapeutic strategy of the
metastatic colorectal cancers, in combination with oral fluoro-
pyrimmidine containing regimen.
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